IMAB
Companies
NASDAQ
I-Mab Sponsored ADR
Health Care
$2.33
+$1.65 (+194.12%)
Price Chart
Overview
About IMAB
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
Market Cap
$152.1M
Volume
248.5K
Avg. Volume
462.7K
P/E Ratio
-0.61224484
Dividend Yield
0.00%
Employees
229.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.03
Moderate Correlation
Volatility
High (0.70)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IMAB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$152.1M
Volume248.5K
P/E Ratio-0.61
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 30, 2022Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025